# AstraZeneca PLC Board and Board Committee appointments

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-board-and-board-committee-appointments/412757896
- Published: 2018-09-06T07:30:59+01:00
- Author: Charlotte Edwards

[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
announced the following Board and Board Committee appointments.

**New Non-Executive Director**

With effect from 1 October 2018, Joseph G. Peter (Joe) is appointed as a Non-Executive
Director and a member of the Audit Committee. Biographical details for Joe Peter
are provided below.

Leif Johansson, Chairman of AstraZeneca, said: “We are very pleased to welcome Joe
Peter to AstraZeneca’s Board. His long and successful executive career in the automotive
industry, his finance expertise and extensive global experience, particularly in
Japan and Asia more broadly, will enable him to make a significant contribution 
to AstraZeneca’s future success.”

**Senior independent Non-Executive Director and Chairman of the Audit Committee**

As previously announced, Rudy Markham intends to retire from the Board at the conclusion
of the Company’s 2019 Annual General Meeting. Succession plans for his role as senior
independent Non-Executive Director and Chairman of the Audit Committee are as follows:

With effect from 1 January 2019, Graham Chipchase will become senior independent
Non-Executive Director of the Company. Mr Chipchase has served as a Director for
six years. He has chaired the Remuneration Committee and been a member of the Nomination
and Governance Committee since April 2015, having previously served as a member 
of the Audit Committee from 2012 to 2014.

With effect from 1 March 2019, Philip Broadley will become Chairman of the Audit
Committee. Mr Broadley became a Director and a member of the Audit Committee in 
April 2017.

**Remuneration Committee; Nomination and Governance Committee**

With effect from 1 December 2018, Philip Broadley will become a member of the Remuneration
Committee and with effect from 1 March 2019, he will become a member of the Nomination
and Governance Committee.

**Joe Peter – biographical details**

Joseph G. Peter (Joe) recently retired as the Chief Financial Officer for Nissan
Motor Company, a position he held for nine years. His wide-ranging role encompassed
responsibility for the full financial strategy of the corporation and working closely
with operational and regional management. Since 2009, he was responsible for the
company’s global Finance activity including Control, Accounting, Treasury, Investor
Relations, Tax and M&A support. In addition, Mr Peter had operational and P&L responsibility
for Nissan’s global sales finance business and was also responsible for the overall
administration of Nissan’s affiliated companies and its global IS/IT operations.
He was a member of Nissan’s Executive Committee and Chairman of the Board of Directors
at Nissan’s sales finance companies located in Japan, United States of America and
Mexico.

More than half of Mr Peter’s 35 years in the automotive industry were spent working
in positions outside the USA, in financial and executive roles in many countries
including Mexico, Sweden, South Korea, China, and Japan. In October 2009, he moved
to Japan to join Nissan as the Chief Financial Officer. Prior to this move, he spent
25 years with General Motors, rising through the company to become Vice President
and Chief Financial Officer of the North American and International Regions.

Mr Peter earned both his MBA and BS in Corporate Finance from Wayne State University.

He is a member of the CNBC Global CFO Council.

In relation to Mr Peter’s appointment, no disclosure obligations arise under paragraphs(
2) to (6) of LR 9.6.13 R of the UK Listing Authority’s Listing Rules. In respect
of paragraph (1) of LR 9.6.13 R, Mr Peter served as a Director of PJSC AVTOVAZ until
2017.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
